NCT07096453

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients: a PK Pilot Study

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.

Conditions

• Kidney Transplant; Complications
• CMV

Interventions

Type	Name	Description
DRUG	Cytogam	Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.

Timeline

• Start date: 2025-10-02
• Primary completion: 2027-08-01
• Completion: 2027-08-01
• First posted: 2025-07-31
• Last updated: 2025-10-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study